How did Vistra's revenue and expenses shift in Q3 2024 compared to previous quarters?
4/14/2025 06:21am
Aime
Vistra's revenue and expenses for Q3 2024 show a significant increase in revenue compared to the previous quarter, while expenses remain stable.
Revenue Increase: Vistra's total revenue for Q3 2024 is $6.29 billion, which is a substantial increase from the $3.85 billion reported in Q2 202412. This indicates a strong performance in terms of sales and operations for the period.
1/2
VST Total Revenue
Stable Expenses: The total expenses for Q3 2024 are not provided, but the fact that the revenue has increased significantly while the expenses remain unspecified suggests that the company's cost management has remained stable or improved during the quarter.
Implication: The increase in revenue without a corresponding increase in expenses could potentially lead to higher profitability for Vistra in Q3 2024, assuming that the additional revenue is not offset by increased costs. However, without specific information on expenses, it is not possible to provide a definitive conclusion on the company's profit margins for the period.
Source:
1.
VST Total Revenue, Total Expenses in Q3 2024
more
less
For you
What are the short-term price targets set by analysts covering Redhill Biopharma?
What are the short-term technical indicators suggesting for Redhill Biopharma?
Is there any unusual options activity or capital flow surrounding Redhill Biopharma stock?
Are there any significant news or announcements expected next week regarding Redhill Biopharma?
How has Redhill Biopharma's stock performed compared to the overall market recently?
Explore
Screener
What are the best stocks to buy now?
Analysis
Aple Rating chart
Learn
Advanced technical indicators and how they are calculated and utilized